Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sorafenib in Lung Cancer: Clinical Developments and Future Directions

Sorafenib in Lung Cancer: Clinical Developments and Future Directions NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER Sorafenib in Lung Cancer: Clinical Developments and Future Directions George Blumenschein, Jr., MD Four standard platinum-based regimens were compared Non-small cell lung cancer (NSCLC) is the leading cause of cancer- in a randomized trial of 1155 patients with untreated ad- related death in the United States. Angiogenesis, primarily mediated vanced inoperable NSCLC. There was no statistically signif- through vascular endothelial growth factor (VEGF), is one of the icant difference between the different regimens in regards to key steps in tumor growth and metastasis. VEGF is now a validated response rate, 1 year, 2 year, or overall survival (OS). Similarly, target for NSCLC based on the results of the Eastern Cooperative no significant difference in response rate, median survival, or Oncology Group trial E4599 which showed that the addition of 1-year survival was seen in a large randomized trial comparing bevacizumab, a VEGF monoclonal antibody, to cytotoxic chemo- docetaxel and pemetrexed in patients with previously treated therapy improves survival compared with chemotherapy alone in NSCLC. Cytotoxic chemotherapy has plateaued in terms of patients with metastatic NSCLC. As NSCLC has complex and efficacy and new approaches are warranted. integrated signaling pathways, a rational http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Sorafenib in Lung Cancer: Clinical Developments and Future Directions

Loading next page...
 
/lp/wolters-kluwer-health/sorafenib-in-lung-cancer-colon-clinical-developments-and-future-RaqUHiItp0

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER Sorafenib in Lung Cancer: Clinical Developments and Future Directions George Blumenschein, Jr., MD Four standard platinum-based regimens were compared Non-small cell lung cancer (NSCLC) is the leading cause of cancer- in a randomized trial of 1155 patients with untreated ad- related death in the United States. Angiogenesis, primarily mediated vanced inoperable NSCLC. There was no statistically signif- through vascular endothelial growth factor (VEGF), is one of the icant difference between the different regimens in regards to key steps in tumor growth and metastasis. VEGF is now a validated response rate, 1 year, 2 year, or overall survival (OS). Similarly, target for NSCLC based on the results of the Eastern Cooperative no significant difference in response rate, median survival, or Oncology Group trial E4599 which showed that the addition of 1-year survival was seen in a large randomized trial comparing bevacizumab, a VEGF monoclonal antibody, to cytotoxic chemo- docetaxel and pemetrexed in patients with previously treated therapy improves survival compared with chemotherapy alone in NSCLC. Cytotoxic chemotherapy has plateaued in terms of patients with metastatic NSCLC. As NSCLC has complex and efficacy and new approaches are warranted. integrated signaling pathways, a rational

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2008

There are no references for this article.